ATLAS fair value
ATLAS has no fair value for this stock today.
Scope Fluidics stock price today, ATLAS forecast and fair value
Healthcare · Diagnostics & Research · Warsaw Stock Exchange · Poland
Prices as of Oct 27, 2026 · PLN
ATLAS has no fair value for this stock today.
50%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Scope Fluidics a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between PLN 146.27 and PLN 167.10; in 9 out of 10, between PLN 130.00 and PLN 188.02. Estimated annual volatility is 41%.
ATLAS does not publish a fair value for SCP.WAR right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks SCP.WAR has traded between PLN 109.00 and PLN 159.80. Today it is 2.1% below that high and 43% above its low.
Its beta is 0.02: it tends to move less than the market.
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. It offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is headquartered in Warsaw, Poland.
Want to see everything about Scope Fluidics?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. It offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is headquartered in Warsaw, Poland.
50%: close to a coin flip. In half of the simulated outcomes, SCP.WAR ends the month between PLN 146.27 and PLN 167.10.
Scope Fluidics's market capitalization is PLN 422M. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 41%. In a typical month, half of the outcomes end between PLN 146.27 and PLN 167.10.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy